The University of Glasgow uses cookies for analytics. Find out more about our Privacy policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
Analytical cookies help us improve our website. We use Google Analytics. All data is anonymised.
Hotjar and Clarity help us to understand our users’ behaviour by visually representing their clicks, taps and scrolling. All data is anonymised.
Dwomoh, L. et al. (2022) M1 muscarinic receptor activation reduces the molecular pathology and slows the progression of prion-mediated neurodegenerative disease. Science Signaling, 15(760), eabm3720. (doi: 10.1126/scisignal.abm3720) (PMID:36378750)
Marsango, S. et al. (2022) Selective phosphorylation of threonine residues defines GPR84-arrestin interactions of biased ligands. Journal of Biological Chemistry, 298(5), 101932. (doi: 10.1016/j.jbc.2022.101932) (PMID:35427647) (PMCID:PMC9118924)
Dwomoh, L. , Tejeda, G. S. and Tobin, A. B. (2022) Targeting the M1 muscarinic acetylcholine receptor in Alzheimer’s disease. Neuronal Signaling, 6(1), NS20210004. (doi: 10.1042/NS20210004)
Osakunor, D. N.M., Ishida, K., Lamanna, O. K., Rossi, M., Dwomoh, L. and Hsieh, M. H. (2022) Host tissue proteomics reveal insights into the molecular basis of Schistosoma haematobium-induced bladder pathology. PLoS Neglected Tropical Diseases, 16(2), e0010176. (doi: 10.1371/journal.pntd.0010176) (PMID:35167594) (PMCID:PMC8846513)
Scarpa, M. et al. (2021) Biased M1 muscarinic receptor mutant mice show accelerated progression of prion neurodegenerative disease. Proceedings of the National Academy of Sciences of the United States of America, 118(50), e2107389118. (doi: 10.1073/pnas.2107389118) (PMID:34893539) (PMCID:PMC8685681)
Brown, A. J.H. et al. (2021) From structure to clinic: design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer’s disease. Cell, 184(24), 5886-5901.e22. (doi: 10.1016/j.cell.2021.11.001) (PMID:34822784)
Vanaerschot, M. et al. (2020) Inhibition of resistance-refractory P. falciparum kinase PKG delivers prophylactic, blood stage, and transmission-blocking antiplasmodial activity. Cell Chemical Biology, 27(7), 806-816.e8. (doi: 10.1016/j.chembiol.2020.04.001) (PMID:32359426) (PMCID:PMC7369637)
Bradley, S. J. et al. (2020) Biased M1-muscarinic-receptor-mutant mice inform the design of next-generation drugs. Nature Chemical Biology, 16(3), pp. 240-249. (doi: 10.1038/s41589-019-0453-9) (PMID:32080630)
Bradley, S. J. et al. (2018) Bitopic binding mode of an M1 muscarinic acetylcholine receptor agonist associated with adverse clinical trial outcomes. Molecular Pharmacology, 93(6), pp. 645-656. (doi: 10.1124/mol.118.111872) (PMID:29695609) (PMCID:PMC5963591)
Rajatileka, S. et al. (2018) Variants of the EAAT2 glutamate transporter gene promoter are associated with cerebral palsy in preterm infants. Molecular Neurobiology, 55(3), pp. 2013-2024. (doi: 10.1007/s12035-017-0462-1) (PMID:28271401) (PMCID:PMC5840247)
Dwomoh, L. et al. (2022) M1 muscarinic receptor activation reduces the molecular pathology and slows the progression of prion-mediated neurodegenerative disease. Science Signaling, 15(760), eabm3720. (doi: 10.1126/scisignal.abm3720) (PMID:36378750)
Marsango, S. et al. (2022) Selective phosphorylation of threonine residues defines GPR84-arrestin interactions of biased ligands. Journal of Biological Chemistry, 298(5), 101932. (doi: 10.1016/j.jbc.2022.101932) (PMID:35427647) (PMCID:PMC9118924)
Dwomoh, L. , Tejeda, G. S. and Tobin, A. B. (2022) Targeting the M1 muscarinic acetylcholine receptor in Alzheimer’s disease. Neuronal Signaling, 6(1), NS20210004. (doi: 10.1042/NS20210004)
Osakunor, D. N.M., Ishida, K., Lamanna, O. K., Rossi, M., Dwomoh, L. and Hsieh, M. H. (2022) Host tissue proteomics reveal insights into the molecular basis of Schistosoma haematobium-induced bladder pathology. PLoS Neglected Tropical Diseases, 16(2), e0010176. (doi: 10.1371/journal.pntd.0010176) (PMID:35167594) (PMCID:PMC8846513)
Scarpa, M. et al. (2021) Biased M1 muscarinic receptor mutant mice show accelerated progression of prion neurodegenerative disease. Proceedings of the National Academy of Sciences of the United States of America, 118(50), e2107389118. (doi: 10.1073/pnas.2107389118) (PMID:34893539) (PMCID:PMC8685681)
Brown, A. J.H. et al. (2021) From structure to clinic: design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer’s disease. Cell, 184(24), 5886-5901.e22. (doi: 10.1016/j.cell.2021.11.001) (PMID:34822784)
Vanaerschot, M. et al. (2020) Inhibition of resistance-refractory P. falciparum kinase PKG delivers prophylactic, blood stage, and transmission-blocking antiplasmodial activity. Cell Chemical Biology, 27(7), 806-816.e8. (doi: 10.1016/j.chembiol.2020.04.001) (PMID:32359426) (PMCID:PMC7369637)
Bradley, S. J. et al. (2020) Biased M1-muscarinic-receptor-mutant mice inform the design of next-generation drugs. Nature Chemical Biology, 16(3), pp. 240-249. (doi: 10.1038/s41589-019-0453-9) (PMID:32080630)
Bradley, S. J. et al. (2018) Bitopic binding mode of an M1 muscarinic acetylcholine receptor agonist associated with adverse clinical trial outcomes. Molecular Pharmacology, 93(6), pp. 645-656. (doi: 10.1124/mol.118.111872) (PMID:29695609) (PMCID:PMC5963591)
Rajatileka, S. et al. (2018) Variants of the EAAT2 glutamate transporter gene promoter are associated with cerebral palsy in preterm infants. Molecular Neurobiology, 55(3), pp. 2013-2024. (doi: 10.1007/s12035-017-0462-1) (PMID:28271401) (PMCID:PMC5840247)
Grants and Awards listed are those received whilst working with the University of Glasgow.
Scarpa, M., Molloy, C. , Jenkins, L. , Strellis, B., Budgett, R., Hesse, S., Dwomoh, L. , Marsango, S., Tejeda, G. , Rossi, M., Ahmed, Z., Milligan, G. , Hudson, B. , Tobin, A. , Bradley, S. and Heptares, S. (2021) Biased M1 muscarinic receptor mutant mice show accelerated progression of prion neurodegenerative disease. [Data Collection]
https://orcid.org/0000-0001-7024-6450